SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neopath (NPTH) -- Ignore unavailable to you. Want to Upgrade?

To: Joseph Ziebarth who wrote (166)3/24/1999 4:24:00 PM
From: Richard Cohen  Read Replies (1) | Respond to of 178
 
Thanx for the input. I've bought some shares over the past few days.Assuming the co. doesn't disappear, the downside risk is minimal at $4/share considering this was a $16 stock earlier in the year.I don't know much about the competition but if Prudential is choosing their product, that's a good thing. This partnership announced yesterday also seems to make the co. viable. This co. is a risk, but at this point I'll take it. If the demand is as great as you say, someone should pick up on it sooner or later.



To: Joseph Ziebarth who wrote (166)4/12/1999 3:00:00 AM
From: Joseph Ziebarth  Read Replies (2) | Respond to of 178
 
A second set of lay-offs caught my friends in production. Seem's that more sales are not expected by the bean counters. I consider this an important sign to hold ... clearly not a good buy sign.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News